Parkinson disease

65,974views

Parkinson disease

NMSK 2022

NMSK 2022

Anatomical terminology
Introduction to the central and peripheral nervous systems
Introduction to the somatic and autonomic nervous systems
Development of the axial skeleton
Bones of the vertebral column
Joints of the vertebral column
Muscles of the back
Vessels and nerves of the vertebral column
Anatomy clinical correlates: Bones, joints and muscles of the back
Superficial structures of the neck: Posterior triangle
Deep structures of the neck: Root of the neck
Anatomy clinical correlates: Vessels, nerves and lymphatics of the neck
Bones of the upper limb
Development of the limbs
Fascia, vessels and nerves of the upper limb
Muscles of the hand
Anatomy of the arm
Anatomy of the brachial plexus
Brachial plexus
Bones of the lower limb
Fascia, vessels and nerves of the lower limb
Muscles of the gluteal region and posterior thigh
Compartment syndrome
Sciatica
Bone remodeling and repair
Ectoderm
Skin histology
Skin anatomy and physiology
Skin and soft tissue infections: Clinical
Papulosquamous and inflammatory skin disorders: Pathology review
Eczematous rashes: Clinical
Skin cancer: Pathology review
Skin cancer: Clinical
Bone histology
Skeletal system anatomy and physiology
Bone disorders: Pathology review
Bone tumors: Pathology review
Paget disease of bone
Pediatric bone and joint infections: Clinical
Joint pain: Clinical
Gout
Rheumatoid arthritis
Nervous system anatomy and physiology
Neuromuscular junction and motor unit
Neuromuscular blockers
Skeletal muscle histology
Muscular system anatomy and physiology
Muscle contraction
Sliding filament model of muscle contraction
Muscle spindles and golgi tendon organs
Neuromuscular junction disorders: Pathology review
Muscle weakness: Clinical
Sympathetic nervous system
Parasympathetic nervous system
Adrenergic receptors
Cholinergic receptors
Opioid agonists, mixed agonist-antagonists and partial agonists
Cholinomimetics: Direct agonists
Substance misuse and addiction: Clinical
Pharmacodynamics: Desensitization and tolerance
Bones of the cranium
Anatomy of the cranial base
Anatomy of the orbit
Anatomy of the eye
Photoreception
Fascia and spaces of the neck
Superficial structures of the neck: Anterior triangle
Eye conditions: Inflammation, infections and trauma: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Pharyngeal arches, pouches, and clefts
Development of the face and palate
Development of the nervous system
Anatomy of the brainstem
Broca aphasia
Wernicke aphasia
Memory
Cerebrospinal fluid
Normal pressure hydrocephalus
Anatomy of the blood supply to the brain
Introduction to the cranial nerves
Cranial nerves
Cranial nerve pathways
Spina bifida
Congenital neurological disorders: Pathology review
Meningitis, encephalitis and brain abscesses: Clinical
Meningitis
Brain abscess
Encephalitis
Spinal cord disorders: Pathology review
Sensory receptor function
Somatosensory receptors
Anatomy of the ascending spinal cord pathways
Anatomy of the descending spinal cord pathways
Anatomy clinical correlates: Spinal cord pathways
Somatosensory pathways
Vitamin B12 deficiency
Motor cortex
Pyramidal and extrapyramidal tracts
Brown-Sequard Syndrome
Syringomyelia
Cauda equina syndrome
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Amyotrophic lateral sclerosis
Olfactory transduction and pathways
Trigeminal neuralgia
Bell palsy
Optic pathways and visual fields
Pituitary adenoma
Anatomy of the oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Anatomy clinical correlates: Oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Vestibulo-ocular reflex and nystagmus
Vestibular transduction
Cerebellum
Dizziness and vertigo: Clinical
Basal ganglia: Direct and indirect pathway of movement
Essential tremor
Huntington disease
Parkinson disease
Movement disorders: Pathology review
Anti-parkinson medications
Medications for neurodegenerative diseases
Hypokinetic movement disorders: Clinical
Multiple sclerosis
Leukodystrophy
Sleep
Toxidromes: Clinical
Cerebral vascular disease: Pathology review
Saccular aneurysm
Intracerebral hemorrhage
Arteriovenous malformation
Ischemic stroke
Transient ischemic attack
Anatomy clinical correlates: Posterior blood supply to the brain
Stroke: Clinical
Epidural hematoma
Brain herniation
Traumatic brain injury: Clinical
Traumatic brain injury: Pathology review
Concussion and traumatic brain injury
Adult brain tumors
Brain tumors: Clinical
Cluster headache
Tension headache
Migraine
Cavernous sinus thrombosis
Idiopathic intracranial hypertension
Migraine medications
Antidiuretic hormone
Hypoprolactinemia
Growth hormone and somatostatin
Oxytocin and prolactin
Anatomy of the limbic system
Frontotemporal dementia
Dementia with Lewy bodies
Vascular dementia
Creutzfeldt-Jakob disease
Syncope: Clinical
Amnesia

Transcript

Watch video only

Parkinson disease, named after Doctor James Parkinson, who first described it, is a progressive neurodegenerative condition characterized by the gradual loss of dopamine-producing neurons in a brain region called the substantia nigra.

Long before the time of Doctor Parkinson, signs of this condition appeared in ancient tales. In Homer’s Odyssey, King Nestor, once a fierce and fearless warrior, slowly changed with age. His hands started to tremble, his steps became sluggish, and his body became stiff, so he could no longer join the battle. His story sounds all too familiar to what we today recognize as Parkinson disease.

Now, to understand what was going on with King Nestor, we need to look deep within the brain, specifically at the basal ganglia. The basal ganglia play a major role in carrying out learned motor plans, such as riding a bike to university. Moreover, they help fine-tune and shape movement while also controlling unwanted or unnecessary motor activity. Basal ganglia do this by modulating signals from the motor part of the thalamus to the motor cortex. Once those signals reach the motor cortex, they travel down the spinal cord to activate muscles, so you can spin those wheels and make it to pathology class on time. At the same time, basal ganglia help regulate muscle tone and help maintain posture.

The basal ganglia include the striatum, which consists of the caudate nucleus and putamen; the globus pallidus; the subthalamic nucleus; and the substantia nigra. When it comes to Parkinson disease, the most important player is the substantia nigra. This phrase literally means black substance and originates from its dark appearance, which comes from melanin-rich neurons. You can picture it as a strong shot of espresso tucked into your midbrain, small, dark, and packed with power.

Now, the substantia nigra consists of two parts. The pars reticulata receives signals from the striatum and sends them down to the thalamus, using the inhibitory, calming neurotransmitter GABA. This helps keep your movements steady and prevents unwanted motions from slipping through. On the other hand, the pars compacta contain dopamine-producing neurons that project to the striatum. This connection forms the nigrostriatal pathway, which supplies the striatum with dopamine and helps initiate movement. Without enough dopamine flowing through it, even simple actions, like reaching for your favorite chocolate bar, can become difficult.

In Parkinson disease, the dopamine-producing neurons in the pars compacta slowly die off. As the brain loses more of these neurons over time, it sends weaker signals through the nigrostriatal pathway, which impairs the initiation and control of voluntary movements.

While most of the time, the underlying cause is unknown, we know that several genetic mutations are associated with Parkinson disease. Based on the type of mutation, we can classify Parkinson disease into autosomal dominant and autosomal recessive types.

Autosomal dominant types are associated with mutations in the SCNA gene, which encodes alpha-synuclein that enables neurons to communicate with each other. When the SCNA gene mutates, the cell produces abnormal alpha-synuclein that misfolds and accumulates within neurons, eventually forming Lewy bodies. These round, eosinophilic structures are the hallmark of Parkinson disease. Next, there’s the LRRK2 gene, which encodes leucine-rich repeat kinase 2, an enzyme that's important with intracellular signaling. When this gene mutates, the enzyme stops working, causing various cellular functions to malfunction.

On the flip side, in the autosomal recessive types, we have mutations of the PARK7 gene, which encodes DJ-1 protein; PINK1 gene, which encodes PINK1 protein; and PARK2 gene, which encodes Parkin protein. These proteins are essential for normal mitochondria functioning. When these proteins don’t work as they should, mitochondrial dysfunction sets in, eventually leading to cell damage and death.

It’s also important to remember that some people with Parkinson disease carry mutations in the GBA1 gene. This gene makes an enzyme called glucocerebrosidase, which helps lysosomes break down and clear out cellular waste. When the enzyme doesn’t work properly, cellular waste accumulates, disrupting normal cell processes and eventually causing cell death. These same mutations are known to cause a lysosomal storage disorder called Gaucher disease. However, we are still not sure how this mutation increases the risk of Parkinson disease.

Regardless of the underlying genetic mutation and type, the loss of melanin-rich neurons causes substantia nigra to look much paler than usual. It’s like pouring milk into that cup of espresso tucked in the brain.

As dopamine-producing neurons die off, dopamine levels in the nigrostriatal pathway gradually decline. With less dopamine available, the brain struggles to initiate movement, which results in clinical features we call parkinsonism. Parkinsonism is a clinical syndrome that includes bradykinesia, rigidity, tremor, and postural instability.

Key Takeaways

Parkinson's is a progressive movement disorder caused by degeneration of dopamine-producing neurons in the substantia nigra, specifically in the pars compacta, which leads to resting tremor, rigidity, problems initiating movement, and postural instability, and for which therapy primarily focuses on increasing brain dopamine.

There is no cure for this condition, but medications can increase dopamine levels in the brain and control tremors. There is also deep-brain stimulation, which involves an implantable device that directly sends electrical signals to the basal ganglia that counteract the abnormal signaling in Parkinson's.

Sources

  1. "Robbins & Kumar Basic Pathology. Available from: ClinicalKey Student, (11th Edition). (pg 754-755) " Elsevier Limited (UK) (2022)
  2. "Robbins & Cotran Pathologic Basis of Disease. Available from: ClinicalKey Student, (10th Edition). (pg-1282-1284)" Elsevier Health Sciences (US) (2020.)
  3. "Crush Step 1 E-Book. Available from: ClinicalKey Student, (3rd Edition).(pg-523-524) " Elsevier Limited (UK) (2023)
  4. "Conn's Current Therapy 2025. Available from: ClinicalKey Student, Page 820-826 " Elsevier Limited (UK) (2024 )